SETD6
Description
The SETD6 (SET domain containing 6, protein lysine methyltransferase) is a protein-coding gene located on chromosome 16.
SETD6 is a protein in humans encoded by the SETD6 gene. It monomethylates the RelA subunit of nuclear factor kappa B (NF-κB) at lysine 310 (RelAK310me1), leading to repression of RelA target genes by recruiting the PKMT G9a-like protein (GLP) which catalyzes H3K9me2 and leads to chromatin silencing and gene repression. In response to stimulation with TNFa and lipopolysaccharide, phosphorylation of RelA at serine 311 (RelAS311ph) by PKCzeta physically blocks the interaction between GLP and RelAK310me1, leading to transcription activation. SETD6 binds and methylates PAK4 both in vitro and in cells at chromatin. Depletion of SETD6 in various cell lines leads to a dramatic reduction in the expression of Wnt/β-catenin target genes. SETD6 binds to, but does not methylate DJ1. Under basal conditions, SETD6 and DJ1 associate with chromatin which inhibits DJ1 to activate Nrf2 transcription activity. In response to oxidative stress, SETD6 mRNA and protein levels are dramatically reduced.
SETD6 is a protein-lysine N-methyltransferase that monomethylates Lys-310 of the RELA subunit of NF-kappa-B complex, leading to down-regulation of NF-kappa-B transcription factor activity. It also monomethylates Lys-8 of H2AZ (H2AZK8me1). SETD6 is required for the maintenance of embryonic stem cell self-renewal and methylates PAK4.
SETD6 is also known as -.
Associated Diseases
- schizophrenia
- urinary bladder carcinoma
- primary familial polycythemia due to EPO receptor mutation
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
- hemoglobin D disease
- alpha thalassemia-intellectual disability syndrome type 1
